- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03592394
Virtual Reality for Chronic Neuropathic Pain
Immersive Virtual Reality for Chronic Neuropathic Pain After Spinal Cord Injury: A Feasibility Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Neuropathic pain (NP) affects 40 to 70% of people with SCI and is a very disabling clinical condition. The definitions of NP as well as its neurophysiology are widely discussed in the literature. Many treatment options have been offered, but provide limited effects, leaving people with SCI with a reduced quality of life.
Pain is a very complex experience that depends strongly on cognitive, emotional, and educational influences. Despite intensive investigations, the cause of neuropathic pain often remains unknown. A careful assessment of the pain including the use of tools to objectively measure pain will help with the diagnosis and the quantification of the damage. These tools include: 1) Laboratory testing that uses quantitative tests and measures objective responses in neurophysiology, sensory evoked potentials...etc.; 2) Quantitative sensory testing, that tests the perception of pain in response to external stimuli; 3) Bedside examination: physicians assessment on location, quality and intensity of pain; 4) Pain questionnaires, depending entirely on the subject's self-reported experience.
When spinal cord injury occurs, the spinal somatosensory circuit is thought to generate aberrant nociceptive impulses that the brain interprets as pain. Thalamic circuits may also serve as amplifiers of nociceptive signals. Sensory deafferentation after injury to the spinal cord produces extensive and long-lasting reorganization of the cortical and subcortical sensory maps. It has been suggested that pain and phantom limb sensations are the consequence of those cortical plasticity change. Therefore, strategies aimed at reversing or modulating the somatosensory neural reorganization may be valuable alternative approaches to neuropathic pain. Immersive virtual reality (IVR) is an emerging approach to the treatment of neuropathic pain conditions in SCI. Despite promising initial studies, IVR therapy has not yet been made widely available to individuals with SCI, because equipment is expensive and can be difficult for clinicians to use, especially those with limited experience with technology. However, with the development of 'plug and play', low-cost IVR devices such as the Oculus Rift, Gear VR and Google Cardboard, IVR no longer requires such specific technical knowledge. As a result, IVR is now a feasible and affordable treatment option for neuropathic pain.
The investigators believe that IVR neurorehabilitation exploits the idea of inducing activation in action observation, motor imagery, and processing systems, which in turn, should activate downstream cortical areas involved in movement and motor imagery. Also, perturbations of the somatosensory system associated with central pain can be reversed or modulated by employing motor imagery and related task execution combined with visual illusions. The investigators hypothesize that SCI patients using immersive IVR training will show improved reduction of neuropathic pain that will outlast the training sessions and transfers into daily life.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New York
-
White Plains, New York, United States, 10605
- Burke Medical Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Presence of chronic neuropathic pain at or below SCI level for at least 6 months following trauma or disease of the spinal cord;
- A pain intensity of at least 4 out of 10 in the numerical rating scale (NRS) in the Neuropathic Pain Scale (NPS) test at both screening (baseline) and randomization (pre-evaluation);
- Stable pharmacological treatment for at least 2 weeks prior to the study and throughout the trial;
- Incomplete lesion (American Spinal Injury Association Impairment Scale, AIS B, C or D; B= motor complete, sensory incomplete; C= sensorimotor incomplete with an average strength of the muscles below the level of the lesion <3, D= sensorimotor incomplete with average muscle strength >3);
- Cervical level of lesion (C2 to T1) with presence of pain in the upper extremities
Exclusion Criteria:
- Presence of severe pain of other origin, such as musculoskeletal pain
- Psychiatric or other neurological disorders
- Head injuries causing cognitive or visual impairment
- Severe vertigo
- Presence of potential risk factors for brain stimulation (TMS): history of seizures, presence of surgically implanted foreign bodies such as a pacemaker, metal plate in the skull, and metal inside the skull;
- Medically unstable
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Somatic IVR (s-IVR)
This group will use an Immersive Virtual Reality (Gear VR) device to focus on encouraging disassociation between pain and visualization and movement of the affected limbs.
Subjects in this group will be exposed to an IVR environment that cycles them through a series of stretching and mobility exercises for the affected limbs bilaterally.
|
Immersing the user in a total visual environment.
|
Active Comparator: Distractive IVR (d-IVR)
This group will use an Immersive Virtual Reality (Gear VR) device to focus on distracting the subject from the pain.
Subjects in this group will be exposed to a variety of engaging landscape IVR environments, without the ability to visualize their own body.
|
Immersing the user in a total visual environment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Neuropathic Pain Scale
Time Frame: Baseline compared with immediately after intervention, and 1 month follow up
|
It includes 11 items, assessing global pain intensity, unpleasantness, and one item which allows the patient to describe the temporal aspects of their pain and its qualities in their own words.
The remaining 8 items assess specific NP qualities: "Sharp," "Hot," "Dull," "Cold," "Sensitive," "Itchy," "Deep," and "Surface."
This is a sensitive tool for measuring changes in neuropathic pain after a therapeutic intervention.
|
Baseline compared with immediately after intervention, and 1 month follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Upper Extremity Motor Score (UEMS)
Time Frame: Baseline, immediately after intervention, and 1 month follow up
|
Clinical measure of motor strength
|
Baseline, immediately after intervention, and 1 month follow up
|
Modified Ashworth Scale
Time Frame: Baseline, immediately after intervention, and 1 month follow up
|
Measure of spasticity scored from 1 (no increase in tone) to 4 (rigid limb)
|
Baseline, immediately after intervention, and 1 month follow up
|
Spinal Cord Independence Measure (SCIM III)
Time Frame: Baseline, immediately after intervention, and 1 month follow up
|
Measures patient's ability to complete activities of daily living
|
Baseline, immediately after intervention, and 1 month follow up
|
Beck Depression Inventory
Time Frame: Baseline, immediately after intervention, and 1 month follow up
|
Self-report measuring characteristic attitudes and symptoms of depression
|
Baseline, immediately after intervention, and 1 month follow up
|
Immersive Tendencies Questionnaire (ITQ)
Time Frame: Baseline, immediately after intervention, and 1 month follow up
|
Measures an individual's sense of engagement and involvement in an activity
|
Baseline, immediately after intervention, and 1 month follow up
|
The Presence Questionnaire
Time Frame: Baseline, post-intervention, and 1 month follow up
|
Measure of presence (ex: selective attention, involvement, immersive response, etc)
|
Baseline, post-intervention, and 1 month follow up
|
Patient's Global Impression of Change
Time Frame: Baseline, immediately after intervention, and 1 month follow up
|
Evaluates both motor function and pain with no change (score 0-1), minimally improved (score 2-3), much improved (score 4-5), and very much improved (score 6-7).
|
Baseline, immediately after intervention, and 1 month follow up
|
Transcranial Magnetic Stimulation
Time Frame: Baseline, immediately after intervention, and 1 month follow up
|
Assess brain reorganization, output and responsiveness as determined by motor threshold, motor evoked potential and amplitude of response.
|
Baseline, immediately after intervention, and 1 month follow up
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Kathleen Friel, PhD, Burke Medical Research Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BRC527
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuropathic Pain
-
University Hospital, Clermont-FerrandFondation ApicilCompletedNeuropathic Traumatic Pain | Pain NRS ≥ 4 | Peripheral Neuropathic Pain | Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4France
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPostherpetic Neuralgia (PHN) | Chemotherapy Induced Neuropathic Pain | Diabetic Peripheral Neuropathic Pain (DPN) | HIV-related Neuropathic Pain (HIV)Colombia, Mexico, Ecuador, Peru, Venezuela
-
University Malaysia SarawakPersatuan Diabetes MalaysiaCompletedNeuropathic Pain, Nociceptive PainMalaysia
-
University Hospital, Clermont-FerrandRecruitingPeripheral Neuropathic PainFrance
-
Daiichi Sankyo Co., Ltd.CompletedCentral Neuropathic PainJapan, Korea, Republic of, Taiwan
-
Hospices Civils de LyonCompletedPharmacoresistant Neuropathic PainFrance
-
Yuhan CorporationCompletedPeripheral Neuropathic PainKorea, Republic of
-
University Hospital, Clermont-FerrandCompletedNeuropathic Pain RebelFrance
-
Ashwin ViswanathanBoston Scientific CorporationNot yet recruitingChronic Pain | Neuropathic Pain | Pain, NeuropathicUnited States
-
University Hospital, Strasbourg, FranceTerminatedPostthoracotomy Pain | Postthoracoscopy Neuropathic PainFrance
Clinical Trials on Immersive Virtual Reality (Gear VR)
-
Cyprus University of TechnologyUniversity of CyprusCompleted
-
Northwestern UniversityRecruitingAnxietyUnited States
-
I.R.C.C.S. Fondazione Santa LuciaRecruitingStroke | Neglect, HemispatialItaly
-
Acibadem UniversityKartal Dr. Lütfi Kirdar City HospitalCompletedRheumatoid Arthritis | Chronic Pain | Virtual RealityTurkey
-
Kessler FoundationCompletedTraumatic Brain InjuryUnited States
-
Tufts UniversityTufts Clinical and Translational Science InstituteCompleted
-
Copenhagen Academy for Medical Education and SimulationCompleted
-
Groupe Hospitalier Paris Saint JosephActive, not recruitingChronic Low-back PainFrance
-
Sheffield Hallam UniversityMedical Research CouncilCompletedUpper Extremity Fracture | Burn; Arm | Exostosis of Elbow | Burn ScaldUnited Kingdom
-
University of California, San FranciscoRecruitingPain, Procedural | Sedation Complication | Procedural AnxietyUnited States